— Know what they know.
Not Investment Advice

CENBF OTC

CEN Biotech, Inc.
1W: +200.0% 1M: +200.0% 3M: +200.0% YTD: +200.0% 1Y: +200.0% 3Y: -99.0% 5Y: -100.0%
$0.00
+0.00 (+200.00%)
 
OTC · Healthcare · Drug Manufacturers - Specialty & Generic · Tech Score Neutral · Power 64 · $19577 mcap · 32M float · 0.0018% daily turnover · Short 100% of daily vol

Balance Sheet Trends

Total Assets
$8M -6.9% ▼
5Y CAGR: -2.7%
Total Liabilities
$10M +0.5% ▲
5Y CAGR: -18.4%
Shareholders Equity
-$2M -38.2% ▼
Cash & Investments
$84K -56.7% ▼
5Y CAGR: -0.3%
Total Debt
$5M -5.6% ▼
5Y CAGR: -21.5%
Net Debt
$5M -3.8% ▼

Assets vs Liabilities & Equity

Year-over-Year Growth

View Full Balance Sheet
Line ItemFY2018FY2019FY2020FY2021FY2022
— Assets —
Cash$3K$4K$2K$193K$84K
Short-Term Investments$0$0$0$0$0
Cash & ST Investments$3K$4K$2K$193K$84K
Net Receivables$0$0$18K$228K$144K
Inventory$0$0-$18$0$0
Other Current Assets$0$0$18$0$0
Total Current Assets$3K$4K$20K$472K$254K
Property, Plant & Equip.$167K$377K$0$236K$145K
Goodwill & Intangibles$6M$5M$5M$6M$6M
Long-Term Investments$1M$2M$1M$1M$1M
Other Non-Current Assets$1M$2M$0$0$0
Total Non-Current Assets$7M$7M$6M$8M$8M
Total Assets$7M$7M$6M$8M$8M
— Liabilities —
Accounts Payable$207K$181K$191K$440K$396K
Short-Term Debt$16M$19M$11M$5M$5M
Deferred Revenue$0$0$0$0$0
Other Current Liabilities$0$0$0$0$0
Total Current Liabilities$24M$31M$15M$10M$10M
Long-Term Debt$3M$1M$78K$32K$31K
Other Non-Current Liab.$1M$720K$1M$0$0
Total Non-Current Liabilities$4M$2M$2M$238K$177K
Total Liabilities$29M$33M$16M$10M$10M
— Equity —
Common Stock$0$0$0$0$0
Retained Earnings-$36M-$41M-$27M-$46M-$47M
Accumulated OCI$0$0$0-$34K-$36K
Total Stockholders Equity-$21M-$26M-$10M-$2M-$2M
Total Liabilities & Equity$7M$7M$6M$8M$8M
— Key Metrics —
Total Debt$19M$20M$11M$6M$5M
Net Debt$19M$20M$11M$5M$5M
Total Investments$1M$2M$1M$1M$1M

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms